Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 61.93 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 83.37 | Oscillator | Sell |
| Williams %R (14) | -4.86 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.63 (Hist 0.72) | Oscillator | Strong Buy |
| Average Directional Index (14) | 20.67 (+DI 20.4 / -DI 13.2) | Trend | Buy |
Current price $134.28
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 19, 26 | Barclays |
| EMA 20 | 130.33 | MA | Strong Buy |
| SMA 20 | 129.12 | MA | Strong Buy |
| EMA 50 | 130.32 | MA | Strong Buy |
| SMA 50 | 131.04 | MA | Buy |
| SMA 200 | 128.92 | MA | Strong Buy |
| maintain |
| Equal Weight |
| Equal Weight |
| Sep 30, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Aug 10, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Apr 21, 26 | Barclays | maintain | Equal Weight | Equal Weight |
| Feb 24, 26 | Barclays | maintain | Equal Weight | Equal Weight |
| Oct 28, 25 | Barclays | maintain | Equal Weight | Equal Weight |
| Oct 14, 25 | Barclays | maintain | Equal Weight | Equal Weight |
| Jul 22, 25 | Barclays | maintain | Equal Weight | Equal Weight |
| Apr 29, 25 | Barclays | maintain | Equal Weight | Equal Weight |
TTM vs. 5-year historical average (annual ratios)
| Metric | CPK | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 21.3x | 24.0x · sector 27.3x | Discount |
| Forward P/E (FY26E) | 20.8x | EPS est. 6.45 | In line |
| Price / Book | 1.9x | 2.2x | In line |
| Price / Sales | 3.3x | 3.4x | In line |
| EV / EBITDA | 12.7x | 13.9x | In line |
| Return on equity | 9.3% | — | Weak |
| Gross margin | 44.7% | 37.1% | Above hist. |
| Debt / Equity | 1.01 | 1.05 | Moderate |
| Piotroski / Altman Z | 6/9 | Z 1.35 | Distress |
Discounted cash flow model
FY2025 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| May 21, 26 | Householder Jeffry M | director, officer: President & CEO | S-Sale | 1,676 @ $125.40 | $210.2K |
| May 21, 26 | Householder Jeffry M | director, officer: President & CEO | S-Sale | 8,321 @ $126.27 | $1.05M |
| May 21, 26 | Householder Jeffry M | director, officer: President & CEO | S-Sale | 3 @ $127.56 | $383 |
| May 20, 26 | Webber Kevin J | officer: Sr VP & Chief Dev Officer | S-Sale | 2,000 @ $127.37 | $254.7K |
| Feb 24, 26 | Galtman Michael D | officer, other: Senior VP | F-InKind | 973 @ $135.05 | $131.4K |
| Feb 24, 26 | Webber Kevin J | officer: Sr VP & Chief Dev Officer | F-InKind | 79 @ $135.05 | $10.67K |
| Feb 24, 26 | Sylvester Jeffery S | officer: Senior VP & COO | F-InKind | 307 @ $135.05 | $41.46K |
| Feb 24, 26 | Moriarty James F | officer: Executive VP & General Counsel | F-InKind | 3,725 @ $135.05 | $503.1K |
Stock news · updated daily
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
Chesapeake Utilities Corporation (NYSE: CPK - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | 1.07 | 1.05 | Miss -1.9% | $201.9M |
| May 6, 2026 | 2.38 | 2.47 | Beat 3.8% | $353.1M |
| Feb 25, 2026 | 1.94 | 1.94 | Beat 0.0% | $258.9M |
| Nov 6, 2025 | 0.90 | 0.82 | Miss -8.9% | $179.6M |
| Aug 7, 2025 | 1.00 | 1.04 | Beat 4.0% | $192.8M |
| May 7, 2025 | 2.28 | 2.22 | Miss -2.6% | $298.7M |
| 8-K | Sep 1, 2026 | 2026-09-01 08:13:07 | View |
| S-8 POS | Aug 14, 2026 | 2026-08-14 16:30:03 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 17:18:06 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 16:49:43 | View |
| 8-K | Jul 13, 2026 | 2026-07-13 11:45:27 | View |
| SC 13G/A | Jul 8, 2026 | 2026-07-08 11:30:22 | View |
Proxy statement (DEF 14A) disclosures